31.95
1.30%
-0.42
Handel nachbörslich:
31.95
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
GlobeNewswire Inc.
Acadia (ACHC), Geisinger JV Begin Construction of New Hospital
Zacks Investment Research
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Why Earnings Season Could Be Great for Arvinas (ARVN)
Zacks Investment Research
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
Zacks Investment Research
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
GlobeNewswire Inc.
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks Investment Research
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Zacks Investment Research
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
GlobeNewswire Inc.
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
Zacks Investment Research
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire Inc.
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Benzinga
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
Zacks Investment Research
Navigating 7 Analyst Ratings For Arvinas
Benzinga
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
Zacks Investment Research
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
Zacks Investment Research
Arvinas Announces Chief Financial Officer Transition
GlobeNewswire Inc.
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
GlobeNewswire Inc.
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
Benzinga
Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?
Zacks Investment Research
Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet
Zacks Investment Research
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
GlobeNewswire Inc.
Encompass Health (EHC) to Post Q4 Earnings: What's in Store?
Zacks Investment Research
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?
Zacks Investment Research
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
GlobeNewswire Inc.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
Zacks Investment Research
Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday
Benzinga
Forecasting The Future: 6 Analyst Projections For Arvinas
Benzinga
Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?
Zacks Investment Research
Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?
Zacks Investment Research
What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock
Zacks Investment Research
Arvinas Appoints Jared Freedberg as General Counsel
GlobeNewswire Inc.
Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?
Zacks Investment Research
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade
Zacks Investment Research
Expert Outlook: Arvinas Through The Eyes Of 9 Analysts
Benzinga
Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?
Zacks Investment Research
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday
Benzinga
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
Zacks Investment Research
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
Benzinga
Kapitalisierung:
|
Volumen (24h):